However, a phase I study for previously treated advanced KRAS-mutant NSCLC showed that defactinib monotherapy had good overall tolerability, moderate clinical activity, and efficacy in heavily pretreated patients with KRAS-mutant NSCLC, irrespective of TP53 and CDKN2A status (Gerber et al., 2020). This evidence concerns the gene KRAS and non-small cell lung carcinoma.